<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600041</url>
  </required_header>
  <id_info>
    <org_study_id>HIPPO1-2004-11-01</org_study_id>
    <secondary_id>2004-004355-18 (EudraCT)</secondary_id>
    <nct_id>NCT00600041</nct_id>
  </id_info>
  <brief_title>Placebo-Controlled Crossover Study for the Investigation of the Effect of Pantoprazole on Cardiac Contractility</brief_title>
  <acronym>HIPPO</acronym>
  <official_title>Heart Issues of PantoPrazOle (HIPPO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herzzentrum Goettingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Göttingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gastroenterology and Endocrinology, University Medicine of Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Statistics, University Medicine of Goettingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herzzentrum Goettingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, negative inotropy of pantoprazole has been shown in isolated human myocardium. This
      study was designed to test the clinical relevance of this finding in healthy volunteers by
      measuring left ventricular function during infusion of a common intravenous high dose regimen
      of pantoprazole.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: Reports on cardiac problems with oral proton pump inhibitors have caused extensive
      safety reviews by the U.S. Food and Drug Administration. We provide additional data on acute
      cardiac effects of an intravenous application.

      Methods: Echocardiography was performed in 18 healthy volunteers after administration of a
      common high dose regimen of pantoprazole (80 mg IV bolus followed by 8 mg/h for 1h) or
      placebo. Design: Randomized, double-blind, placebo-controlled crossover trial.

      Results: EF [%, means+/-S.E.] in the treatment group (placebo group) was 60.7+/-1.1
      (61.2+/-1.7) at baseline, and 62.6+/-1.1 (62.1+/-1.9), 64.7+/-1.6 (63.5+/-1.3), 62.6+/-1.6
      (61.0+/-1.6) and 63.0+/-1.4 (61.8+/-1.5) at 7.5, 15, 30 and 60 min after bolus application,
      respectively (p = n.s.). Similarly, no significant changes were found for cardiac output,
      cardiac index, blood pressure, and heart rate. In contrast, gastric pH that was used as a
      treatment control was significantly increased 60 min after application of pantoprazole as
      compared to baseline and to placebo.

      Conclusions: Pantoprazole for injection is safe in healthy subjects with respect to cardiac
      contractile function. However, in view of recent reports of negative inotropy of the drug
      further studies in heart failure patients are required.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Echocardiographic ejection fraction</measure>
    <time_frame>60 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac index</measure>
    <time_frame>60 min</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pantoprazole IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0.9% IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <description>80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Pantozol i.v.</other_name>
    <other_name>Protonix I.V.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical infusion manner like experimental arm</description>
    <arm_group_label>B</arm_group_label>
    <other_name>NaCl 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 or &lt; 40 years

          -  No signs of overt heart failure

          -  Echocardiographic ejection fraction &gt;= 55%

          -  Body Mass Index 20 - 25 kg/m²

          -  Excellent sonographic conditions

          -  Non-smoker

          -  Informed consent

        Exclusion Criteria:

          -  History of cardiac disease

          -  History of other relevant pre-existing illness

          -  Pathologic findings in clinical examinations

          -  Pathologic echocardiographic findings

          -  Pathologic ECG findings

          -  Pathologic laboratory findings

          -  Pregnancy and lactation

          -  No or insufficient contraception

          -  Intolerance of pantoprazole

          -  Alcohol or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerd Hasenfuss, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Goettingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Cardiology and Pneumology; Herzzentrum Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.herzzentrum-goettingen.de/</url>
    <description>Herzzentrum Goettingen - Heart Center of Goettingen</description>
  </link>
  <results_reference>
    <citation>Schillinger W, Hörnes N, Teucher N, Sossalla S, Sehrt D, Jung K, Hünlich M, Unsöld B, Geiling B, Ramadori G, Hilgers R, Schwörer H, Hasenfuss G. Recent in vitro findings of negative inotropy of pantoprazole did not translate into clinically relevant effects on left ventricular function in healthy volunteers. Clin Res Cardiol. 2009 Jun;98(6):391-9. doi: 10.1007/s00392-009-0012-6. Epub 2009 Mar 20.</citation>
    <PMID>19301059</PMID>
  </results_reference>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2008</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2008</study_first_posted>
  <last_update_submitted>March 22, 2009</last_update_submitted>
  <last_update_submitted_qc>March 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Gerd Hasenfuss/Prof. Dr., Head of dept. of Cardiology and Pneumology</name_title>
    <organization>Herzzentrum Goettingen, Dept. of Cardiology and Pneumology</organization>
  </responsible_party>
  <keyword>Proton Pump Inhibitors</keyword>
  <keyword>pantoprazole</keyword>
  <keyword>Cardiac Output</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>adverse effects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

